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Artery Bypass ModelJohn Freeman,1 Aaron Chen,1 Roy J. Weinberg,1 Tamuru Okada,2 Changyi Chen,1
and Peter H. Lin,1,3 Houston, Texas, Pasadena and Los Angeles, CaliforniaBackground: Bypass graft thrombosis remains a significant mode of failure in prosthetic graft
revascularization. The purpose of this investigation was to evaluate the long-term thromboresist-
ant effect of heparin-bonded expanded polytetrafluoroethylene (ePTFE) graft using Carmeda
BioActive Surface technology in a canine model.
Methods: Bilateral femorofemoral artery bypass grafts with ePTFE grafts were performed in 25
adult grayhound dogs. In each animal, a heparin-bonded ePTFE graft (Propaten, WL Gore) was
placed on one side, whereas a control nonheparin graft was placed on the contralateral side.
The graft patency was assessed at 1, 6, 12, 18, and 24 months (n ¼ 5 per group) following
the bypass. Heparin bioactivity of the graft material was analyzed. The effect of intimal hyperpla-
sia was also assessed.
Results: All bypass grafts were patent at 1 month. Significantly greater patency rates were
noted in the Propaten group compared to the control group at 12, 18, and 24 months, which
were 84%, 80%, and 80% vs. 55%, 35%, and 20%, respectively (P < 0.02). There was a signif-
icant reduction in the anastomotic neointimal area and neointimal cell proliferation in Propaten
grafts compared with control grafts at all groups between 6 and 24 months (P < 0.05). Heparin
bioactivity as measured by antithrombin binding assay was demonstrated in the Propaten graft
between 1 and 24 months. Mean heparin activities on Propaten grafts ranged from 26.3 ± 6.4
pmol/cm2 to 18.4 ± 8.7 pmol/cm2 between 1 and 24 months, which were significantly greater
than the control group (P < 0.001). Differences between mean heparin activities of explanted
Propaten graft samples at the various time points were nonsignificant (P > 0.05).
Conclusions: Heparin-bonded ePTFE graft provides a thromboresistant surface and reduced
anastomotic intimal hyperplasia at 2 years. The stable heparin bioactivity of the Propaten graft
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The prevalence of lower extremity arterial occlu-
sive has risen steadily in recent decades due in
part to the rise of the aging population. For patients
with severe lower extremity arterial occlusive dis-
ease who require bypass reconstruction, the saphe-
nous vein graft has long been considered as the
ideal conduit of choice because of its autogenous
property and proven patency. On the other hand,
in patients who do not have adequate saphenous
vein graft, prosthetic conduit such as expanded
polytetrafluoroethylene (ePTFE) bypass graft has
become a useful alternative conduit of choice.
Although researchers have shown comparable
patency rates of ePTFE bypass graft versus
autogenous saphenous vein in above-knee femoro-
popliteal artery bypass grafting,1 its clinical perfor-
mance remains suboptimal when placed in small
caliber vessels such as infrapopliteal or tibial artery
due to graft thrombogenicity and graft-related
intimal hyperplasia.
In an effort to improve the graft patency and
enhancebiomaterial thromboresistance, researchers
have developed various heparin-bonding technolo-
gies by incorporating heparin to ePTFE biomaterial
surface.2,3 We have previously reported the benefi-
cial role of heparin-coated ePTFE grafts and stents
with reduced thrombogenicity, reduced intimal hy-
perplasia, and improved patency outcomes in both
canine and baboon models.4e7 Although these
heparin-bonding modalities generally show excel-
lent short-term thromboresistant properties, long-
term benefits of graft patency is generally reduced
due to the loss of heparin bioactivity on the biomate-
rial surface.8e10 Scientists have made significant
strides in the thrombosis research with biomaterial
modification to improve the heparin retention effi-
cacy to enhance prosthetic graft thromboresistance.
A bioactive heparin-bonded ePTFE graft utilizing
Carmeda BioActive Surface (CBAS) technology
(Carmeda, WL Gore, Flagstaff, AZ), which utilizes a
covalent end-point attachment method to bind hep-
arin to the prosthetic graft surface, represents an
exciting biomaterial strategy to provide a long-term
heparin bioactivity.11,12 Clinical studies have shown
sustained functional heparin bioactivity with resul-
tant reduction of platelet deposition and decreased
thrombogenicity in oxygenator membranes, extra-
corporeal circuits, and heart-assist devices.12e15
In this present study, we hypothesized that CBAS
heparin immobilization on an ePTFE vascular graft
would result in stable and long-term heparin
bioactivity. Specifically, we investigated the long-
term effect of heparin-bonded ePTFE graft inthromboresistance, platelet deposition, and intimal
hyperplasia in a canine model.MATERIALS AND METHODSBypass GraftsHeparin-bonded prosthetic grafts used in this study
were commercially available ePTFE grafts (internal
diameter, 6 mm; length, 5 cm; Propaten, W.L. Gore
& Associates, Inc. Flagstaff, AZ). These graft surfaces
incorporated immobilized heparin using the propri-
etary CBAS technology, which produced a surface
microstructure with stable and covalently bound
heparin. With a single-point attachment method,
the heparin active sitewas available for binding anti-
thrombin III (AT-III) and contained catalytic func-
tion. The heparin activity and concentration on the
ePTFE graft were approximately 53 pm AT-III up-
take/cm2 and 15 mg/cm2, respectively.8 Control or
noneheparin-bonded grafts were also commercially
available ePTFE grafts (internal diameter, 6 mm;
length, 5 cm; GORE-TEX, W.L. Gore & Associates).Femoral Artery Bypass ModelTwenty-five grayhound dogs weighing 32.7e38.6 kg
(mean 36.7 kg) were used in this study. Anesthesia
was induced with thiopental sodium (10e20 mg/kg
intravenously). All procedures and care were per-
formed in accordance with the Guideline for the Care
and Use of Laboratory Animals (NIH publication No.
80-23, eighth edition, revised 2011) and the Food
and Drug Administration’s Good Laboratory Practice
for Non-clinical Laboratory Studies Regulations (21
CFR, Part 58). Prophylactic cefazolin (1gm, Kefzol;
Marsam Pharmaceuticals, Cherry Hill, NJ) was
administered intravenously. Animals were given
thiopental sodium (Pentothal; Abbott Laboratories,
North Chicago, IL; 10 mg/kg IV). Endotracheal intu-
bationwasperformed, andanesthesiawasmaintained
with 1% isoflurane (Rhone-Poulenc, Bristol, UK). All
animals underwent bilateral femorofemoral artery
bypass grafting with heparin-bonded Propaten ePTFE
graft on one side and control graft on the contralateral
side. Propaten versus control grafts were randomly
alternated between right and left femoral segments.
All animals received systemic heparin (100 u/kg) dur-
ing the timeofanastomotic reconstruction.All anasto-
moses were created using end-to-side anastomoses
and continuous 6-0 polypropylene sutures (Ethicon,
Somerville NJ). Femoral arteries were then ligated at
the regions immediately adjacent to the heels of prox-
imal and distal anastomoses, with the restoration
of blood flow through the grafted segments.
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postoperatively. Graft implant durations were 1, 6,
12, 18, and 24 months. Arterial duplex ultrasound
was performed on a biweekly basis following graft im-
plantation to assess the graft patency.Histology and MorphometryFig. 1. Graft patency rates between the Propaten and
control group.Bromodeoxyuridine (BrdU; Sigma Chemical Co, St
Louis, MO), 50 mg/kg dissolved in 50 mL of normal
saline solution, was administered subcutaneously
24 hr before graft explanation using methods which
we previously described.4e7 Grafts, and adjacent
3-cm segments of attached vessel at each anasto-
mosis, were harvested and fixed in 10% buffered
formalin (Baxter Diagnostics Inc., McGaw Park,
IL). Following fixation, the grafts were embedded
in paraffin and sectioned at the midpoint between
the heel and toe of each anastomosis at a distance
of 2 mm from the heel of each anastomosis and at
5-mm intervals along the entire graft length. Five-
micron sectionswere cut and stainedwith hematox-
ylin and eosin and with Verhoeff-Masson stain. Cell
ingrowth overlying the luminal surface of the graft
adjacent to the anastomosis was considered to be
graft neointima. Cell proliferative tissue overlying
the internal elastic lamina of native vessels was
considered to be vessel neointima. Morphometric
measurements of the area of anastomotic neointima
were performed with computer image analysis soft-
ware (Optimas, Bioscan, Inc., Edmonds, WA) on a
magnified image relayed from a microscope-
mounted video camera to a digitizing pad and video
monitor (Thomas Optical, Columbus, GA) as previ-
ously described.16,17 The graft and native vessel neo-
intimal tissues at the anastomoses were measured
separately. Three tissue blocks were generated be-
tween the heel and toe of each anastomosis. From
the 3 tissue blocks, mean values of morphometric
measurements and cell proliferation rates were re-
ported. All the tissue samples were analyzed in a
blinded manner with respect to whether they
were derived from heparin-coated or control grafts.ImmunocytochemistryThe avidin-biotin complex immunoperoxidase pro-
cedure (LSAB Kit, Dako Co., Carpenteria, CA) was
used to identify determinants characterizing neoin-
timal cell types and proliferating cells as previously
described.16,17 Briefly, immunostaining for a-actin
and factor VIIIerelated antigen was performed to
identify smooth muscle cells and endothelial cells,
respectively. Proliferating cells were identified
with anti-BrdU monoclonal antibody (Dako CO).
BrdU-positive cells were quantified manually witha cell counting technique on a calibrated micro-
meter grid with microscopy (400). In each field,
all the cells were counted, and the number of posi-
tively stained cells was expressed as a percentage
of total cells to arrive at the BrdU index. Aminimum
of 10 fields was quantified per section.Heparin Bioactivity AssayHeparin bioactivity was measured as the capacity of
the surface-bound heparin to bind antithrombin.18
At the time of graft harvest, 2 representative 2-cm
segments from the midsegment of each graft were
rinsed in isotonic saline, cleared of endogenous hep-
arin in buffered 0.6-M borate in 0.01-MNaCl (pH 9),
and rinsed again with deionized H2O. Samples then
were assayed for luminal-surface heparin activity
measured as capacity to bind antithrombin and
expressed as antithrombin bound per unit surface
area (pmol/cm2) as described.18Statistical AnalysisAll statistical analyses were performed using a statis-
tical software program JMP 10 (SAS Institute, Gary,
NC). Bypass graft patency rates as assessed by arterial
duplex ultrasound between the Propaten and con-
trol grafts were evaluated with Kaplan-Meier life
table analysis and compared with a log-rank test.
One-way analysis of variance was used to compare
mean heparin activities on the Propaten and control
graft samples from the in vivoheparin function study.
Comparisons of neointimal areas and cell prolifera-
tion between the heparin-treated grafts and the con-
trol grafts were made with the Student’s t-test
(2-tailed) for paired data. The values are given as
the mean ± the standard error. The results were
considered significant if the P value was less than
0.05.
Fig. 2. Comparison of heparin bioactivity between the Propaten and control group.
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AssayAll animals survived the duration of the study.
Significantly greater patency rates were noted in
the Propaten group compared to the control group
at 12, 18, and 24 months, which were 84%, 80%,
and 80% vs. 55%, 35%, and 20%, respectively
(P < 0.02; Fig. 1). Heparin bioactivity was detected
on all explanted Propaten grafts at each time point
throughout the study duration. Comparison of the
heparin activities between the 2 groups was dis-
played in Figure 2. Significantly greater mean hepa-
rin bioactivity was detected in the Propaten group at
each explant period compared with the control
group (P < 0.001). Mean heparin activities on the
Propaten graft samples ranged from 26.3 ± 6.4
pmol/cm2 measured at 1 month to 18.4 ± 8.7
pmol/cm2 at 24 months. The mean heparin activity
at 24 months was 19.4 ± 8.3 pmol/cm2. Mean hepa-
rin activities of control grafts were near or below the
lower detection limit of the assay. Differences be-
tweenmeanheparin activities of explantedPropaten
graft samples at the various time points were nonsig-
nificant (P > 0.05).Neointimal Hyperplasia and Neointimal
Cell ProliferationMeasurable neointimal hyperplasia was present at
both proximal and distal anastomoses of the grafts
in both Propaten and control grafts. Smooth muscle
cells were the major type of anastomotic neointimalcells identified by a-actin immunostaining. Endothe-
lial cells covered the surfaces of all the anastomotic
neointima as shown with factor VIIIerelated antigen
immunohistochemical staining.Results ofneointimal
hyperplasia at the anastomoses between the Propaten
and the control groups are shown in Table I. Signifi-
cant reduction of graft intima hyperplasia at both
proximal and distal anastomoses in the Propaten
graftswasnotedas comparedwithproximal anddistal
anastomoses in the control grafts at 6, 12, 18, and
24 months (P < 0.05). However, there was no
difference in vessel neointimal area at anastomoses
between the Propaten and the control groups.
Neointimal cell proliferation was evaluated by
BrdU incorporation staining, and the results are
displayed in Table II. Smooth muscle cells were the
major type of anastomotic neointimal cells identified
by a-actin immunostaining. No difference in neointi-
mal BrdU-labeling indexbetweenproximal and distal
anastomoses of grafts was found. However, when
comparing the cell proliferation between the graft
neointima between the Propaten and control grafts,
the BrdU-labeling index was significantly less in the
Propaten grafts as compared with the control grafts
at 6, 12, 18, and 24months (P< 0.05, Table II). There
was no significant difference in BrdU-labeling index
in the native vessel at the anastomoses between the
Propaten and control groups at the various time
points during the study (Table II).DISCUSSION
The introduction of ePTFE bypass graft in the 1970s
revolutionized the field of lower extremity
Table I. Effects of heparin-bonded Propaten grafts versus control grafts on anastomotic neointimal areas
of canine femoral artery bypass grafting
Duration Location Propaten graft (mm2) Control graft (mm2) P value
1 month Proximal anastomosis
Graft neointima 0.47 ± 0.27 0.53 ± 0.24 NS
Vessel neointima 0.29 ± 0.19 0.31 ± 0.16 NS
Distal anastomosis
Graft neointima 0.37 ± 0.18 0.36 ± 0.08 NS
Vessel neointima 0.37 ± 0.159 0.35 ± 0.11 NS
6 months Proximal anastomosis
Graft neointima 0.38 ± 0.21 1.01 ± 0.28 0.02
Vessel neointima 0.28 ± 0.17 0.29 ± 0.14 NS
Distal anastomosis
Graft neointima 0.35 ± 0.09 0.46 ± 0.15 NS
Vessel neointima 0.34 ± 0.16 0.36 ± 0.12 NS
12 months Proximal anastomosis
Graft neointima 0.45 ± 0.23 1.31 ± 0.29 0.02
Vessel neointima 0.31 ± 0.18 0.33 ± 0.17 NS
Distal anastomosis
Graft neointima 0.36 ± 0.17 0.73 ± 0.23 0.04
Vessel neointima 0.36 ± 0.19 0.38 ± 0.18 NS
18 months Proximal anastomosis
Graft neointima 0.43 ± 0.24 1.41 ± 0.32 0.02
Vessel neointima 0.34 ± 0.22 0.36 ± 0.16 NS
Distal anastomosis
Graft neointima 0.38 ± 0.24 1.15 ± 0.25 0.03
Vessel neointima 0.35 ± 0.19 0.39 ± 0.18 NS
24 months Proximal anastomosis
Graft neointima 0.53 ± 0.27 1.53 ± 0.32 0.01
Vessel neointima 0.36 ± 0.17 0.38 ± 0.15 NS
Distal anastomosis
Graft neointima 0.42 ± 0.25 1.21 ± 0.31 0.02
Vessel neointima 0.36 ± 0.18 0.39 ± 0.19 NS
NS, not significant.
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viable graft alternative particularly in patients who
did not have adequate or available autogenous vein
conduits.19 Despite advances in biomaterial science,
prosthetic graft occlusion remains a significant chal-
lenge in clinical practice. It is well acknowledged
that bypass graft failure can be caused by early
thrombotic occlusion, neointimal hyperplasia, or
late atherosclerotic disease progression. Heparin
bonding of ePTFE biomaterial has been shown to
reduce thrombotic formation and improve graft
patency rate in multiple studies.2,4,5,8,9,13 The
findings of our study are distinctive as it demon-
strated that heparin-bonded ePTFE graft provided a
thromboresistant bioactivity and reduced intimal hy-
perplasia comparedwithnoneheparin-bondedgraft.
Furthermore, our study represents the longest in vivo
study to date which validated the sustained heparin
bioactivity with persistent thromboresistance andreduced intimal hyperplasia in a chronic canine
bypass model.
The formation of thrombus on the graft luminal
surface by the circulating blood represents the most
immediate mode of graft failure. Researchers have
attempted to reduce graft surface thrombogenicity
by coating anticoagulant or antiplatelet drug to the
graft biomaterial.8,10,20 However, early reports of
such efforts have produced suboptimal results with
inconsistent bioactivity of the anticoagulant mole-
cule secondary to a widely varied degree of drug
elusion once the bypass graft is exposed to the circu-
lating blood. The CBAS heparin ePTFE graft uses a
polymeric base matrix, which binds the heparin
molecule to the graft surface in a manner that pre-
serves the anticoagulant activity using a covalent
end-point linking technology.21 The anticoagulant
activity of the end-point bonded heparin, referred
to as bioactivity, is measured as the capacity to bind
Table II. Effects of heparin-bonded Propaten grafts versus control grafts on neointimal cell proliferation
at the femoral bypass graft anastomosis
Duration Neointimal cell proliferation Propaten graft (mm2) Control graft (mm2) P value
1 month Graft neointima (BrdU%) 3.08 ± 0.42 4.83 ± 0.82 0.04
Vessel neointima (BrdU%) 3.75 ± 0.54 3.62 ± 0.45 NS
6 months Graft neointima (BrdU%) 3.28 ± 0.37 6.24 ± 0.72 0.02
Vessel neointima (BrdU%) 4.12 ± 0.57 4.43 ± 0.47 NS
12 months Graft neointima (BrdU%) 3.48 ± 0.38 6.37 ± 0.79 0.02
Vessel neointima (BrdU%) 3.95 ± 0.56 4.02 ± 0.42 NS
18 months Graft neointima (BrdU%) 4.23 ± 0.46 7.21 ± 0.86 0.02
Vessel neointima (BrdU%) 4.21 ± 0.68 4.38 ± 0.65 NS
24 months Graft neointima (BrdU%) 4.76 ± 0.47 7.42 ± 0.85 0.02
Vessel neointima (BrdU%) 4.17 ± 0.78 4.25 ± 0.39 NS
NS, not significant.
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tion inhibitor in the circulating blood but also a key
protein for the heparin-mediated control of blood
coagulation.18 The CBAS-immobilized heparin bio-
surface previously has been shown to catalyze the
rate of inactivation of thrombin by antithrombin
effectively blocking the conversion of fibrinogen to
fibrin, as well as block Factor XII initiation of the
coagulation cascade.22,23 In addition, the CBAS hep-
arin surface is known to influence initial protein
deposition on various biomaterials.24 Consequently,
the CBAS-treated ePTFE heparin surface is more
hemocompatible due to its influence on protein
adsorption during initial blood contacting events.25
Clinical applications of the CBAS immobilized hepa-
rin surface include cardiovascular biomaterials such
as cardiopulmonary bypass circuitry,26 ventricular
assisteddevice,12 vascular graft,11,27 and stent graft.28
Our laboratory has previously reported the antith-
rombotic characteristics of heparin-coated ePTFE
grafts and stents in canine and baboon models.4e7
The effectiveness in reducing surface-induced
thrombus formation has been linked to reduction
in inflammatory cytokine activation in numerous
in vitro studies.29,30 In a clinical study which evalu-
ated an extracorporeal Berlin Heart assist device,
CBAS-immobilized heparin biomaterial has been
shown to reduce the frequency and thickness of
thrombotic deposits, thereby likely reducing compli-
cations related to thromboembolism.31
The finding of reduced thrombus formation in
our study is consistent with other reports, which
showed reduced platelet deposition on CBAS-
immobilized devices, including cardiopulmonary
bypass circuitry and oxygenator membrane.12,32
Improved graft patency and reduced thrombogenic-
ity with sustained heparin bioactivity at 6 monthswas also reported in a sheep carotid artery bypass
model using heparin-coated ePTFE graft.33 The
bioactivity of heparin-bonded ePTFE surface with
resultant decreased platelet adherence, decreased
thrombus formation, and reduced inflammatory
response has also been shown in extracorporeal cir-
cuits, and heart-assist devices up to 2 years.12,34,35
Kocsis et al.25 analyzed CBAS-heparin treated coro-
nary stents in a baboon ex vivomodel and reported a
significant decrease in platelet deposition on hepa-
rinized stents compared to untreated control stents.
In addition, the decreased platelet deposition in
heparin-treated stents was correlated with the
immobilized high AT-affinity heparin fraction.
These researchers noted that significantly reduced
platelet deposition correspondedwith heparin activ-
ity as low as 7 pmol/cm2.25 Begovac and coworkers
tested CBAS immobilized heparin ePTFE graft in a
canine carotid artery bypass model, and demon-
strated sustained antithrombin bioactivity was pre-
sent at 12 weeks in the heparinized grafts.11
Furthermore, significantly greater thrombus-free
luminal surface was found on the heparin treated
grafts when compared to non-heparin treated grafts.
The authors reported a stable heparin activity in all
CBAS-ePTFE surfaces with levels ranging between
15 and 25 pmol/cm2 up to 12 weeks, which were
well above the activity shown to reduce platelet
deposition on the CBAS-treated surface. These re-
sults are consistent with our results in which we
showed sustained heparin bioactivity between
18.4 ± 8.7 pmol/cm2 and 26.3 ± 6.4 pmol/cm2 dur-
ing the 2 years of graft implantation duration.
Our study showed that CBAS-immobilized hepa-
rin graft resulted in significantly less anastomotic
neointimal hyperplasia when compared to none
heparin-treated grafts, based on the evidence of
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(Tables I and II). These results are in linewithour pre-
vious reports in terms of reduced intimal hyperplasia
in heparinized grafts compared with nontreated
grafts in animalmodels.4,5 Theantiproliferative effect
of heparin on smoothmuscle cell has been proven in
multiple in vitro studies using human, baboon,
bovine, and rat cell cultures.36,37 Studies have
demonstrated that the inhibitory effect of heparin
on cultured smoothmuscle cell proliferation ismedi-
ated via inhibition of DNA synthesis and by downre-
gulation of the transcription gene necessary for cell
passage fromG0 throughG1 and into theSphase.
38,39
Researchers have also discovered other possible
mechanisms by which heparin inhibits neointimal
proliferation. For instance, the antiproliferative
properties of heparin may in part be mediated
through inhibition of a second messenger pathway
resulting in proto-oncogene expression in cell
cycling.40 Heparin not only inhibits intracellular pro-
tein kinase activity during signal transduction41 but
also downregulate transcription activator proteins.42
Moreover, it can modulate the function and expres-
sion of numerous growth factors. It has also been
shown that heparin can inhibit basic fibroblast
growth factor (bFGF)emediated growth responses
of both endothelial and smooth muscle cells as well
as downregulate the bFGF expression in the wall of
injured arteries.43 Heparin similarly can inhibit
epidermal growth factor receptor expression and po-
tentiates the inhibitory properties of transforming
growth factor b by releasing it from a carrier pro-
tein.44,45 Finally, heparin selectively inhibits the pro-
duction of certain proteases that are critical for
degrading extracellular matrix which can diminish
cellular proliferation. These proteases include
tissue-type plasminogen activator, interstitial colla-
genase, stromelysin, and gelatinase.46 These results
suggest that heparin plays a vital role in modulating
smooth muscle cell migration and neointimal prolif-
eration via a complex biochemical and cellular
cascade. Therefore, new treatment strategies which
target these cellular pathways by incorporating hep-
arin on prosthetic vascular biomaterial may poten-
tially improve the graft patencyandclinical outcome.
The beneficial effect of CBAS-immobilized hepa-
rin in cardiovascular application has been validated
by numerous clinical investigators.12,25,47e50
Studies have shownCBAS-coated heparinized coro-
nary stents can reduce subacute thrombosis,51
decreasemajor adverse events compared to coronary
balloon angioplasty,52 and result in superior patency
rates.48 Kaufmann et al.53 analyzed CBAS-heparin
coated EXCOR ventricular assist device pumps up
to 190 days of clinical use and found that thereplacement rate of pumps with the CBAS heparin
treatment was significantly reduced compared with
uncoated pumps, due in part to decreased thrombus
deposition and thromboembolic complications. In a
similar study which analyzed CBAS treated ventric-
ular assist device pump, Werkkala et al.12 showed
sustained heparin bioactivity up to 461 days of clin-
ical usage. The clinical benefit of CBAS-heparinized
ePTFE graft, or Propaten graft, has similarly been
investigated in lower extremity revascularization.
Samson et al.54 reported a large clinical study in
which they analyzed the outcomes of femoropopli-
teal artery bypass between 234 Propaten grafts and
123 standard ePTFE grafts and found superior
primary patency rates in both above-knee and
below-knee Propaten graft when compared to non-
heparinetreated grafts. The Propaten European
Product Evaluation II multicenter prospective Euro-
pean registry observed 12-month primary patency
rates of 82.7% in above-knee and 74.2% in below-
knee heparin-bonded femoropopliteal grafts.49
A prospective randomized multi-institutional Scan-
dinavian study documented a 12-month primary
patency rate of 80.4% in the heparin-bonded femo-
ropopliteal grafts, which was significantly higher
compared to 69.6% rate observed in the standard
ePTFE group of that study.50 Dorigo et al.55 reported
their institutional experience of femoropopliteal
below-knee bypass using standard PTFE versus
heparin-bonded Propaten graft. Their results
showed significantly improved 18-month patency
rate of Propaten graft compared with the standard
graft,whichwere 40%and53%, respectively. Taken
altogether, these clinical reports underscored the su-
perior clinical outcome of CBAS-heparin treated
vascular biomaterials in terms of superior patency
and improved outcomes compared to nonehepa-
rin-treated biosurface.
In conclusion, this study demonstrated long-term
thromboresistant property of heparin-bonded Prop-
aten graft, which incorporates CBAS-ePTFE heparin
surface to provide stable and sustained heparin
bioactivity. In addition, reduced graft neointimal
hyperplasia was demonstrated in heparin-bonded
Propaten graft compared with the control untreated
graft in our chronic animal bypass model. Our data
support the use of CBAS-ePTFE heparin-bonded
bypass in clinical application due to the long-term
thromboresistant bioactivity.
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